Brussels & Kuala Lumpur, 14 August 2015

Belgium-based OncoDNA SA, The Cancer Theranostic Company, which provides a complete solution from tumor molecular profiling (OncoDEEP) to liquid biopsy (OncoTRACE), hence providing oncologists with treatment recommendations and drug response monitoring, has recently finalized a distribution agreement with Genesis Genome, a leading precision medicine provider in the field of oncology in Malaysia that will bring affordable and state-of-the-art theranostic analyses to the Malaysian population.

Genesis Genome has chosen OncoDNA as its exclusive supplier of clinical grade molecular theranostic using the OncoDEEP DX (65 genes) and Clinical (409 genes) cancer panels in combination with the Package Plus, a cancer specific package of different IHCs and other tests designed to analyse key proteins’ presence and activity, translocations, etc. The collaboration agreement with OncoDNA will enable Malaysian physicians to access this medical innovation, providing them with clinically relevant interpretations of patients' tumors by using the OncoSHARE web platform designed by OncoDNA.

This collaboration agreement confers distribution exclusivity in Malaysia for Genesis Genome. This is the sixteenth (16) exclusive agreement granted by OncoDNA.

Genesis Genome focuses on personalized treatments. Its goal is to provide each individuals based on their own genetic make-up with a more precise targeted treatments plan. They empowers physicians to select appropriate customized treatment plans and medications more efficiently and effectively so that success rate are higher for their patients, in a way that will help extending life in a more meaningful way.

“We are very happy to working with OncoDNA to provide cutting edge technology to help and guide cancer patients and physicians based on individual genetic makeup of cancer. This will truly revolutionize cancer treatment in Malaysia by providing right choice for the best available treatments.” said Kelly Teo.

When just sequencing a patient’s tumor tends to demonstrate its limits to provide oncologists with accurate treatment strategy, OncoDNA aims at providing medical innovations based on the unique combination of targeted sequencing and molecular pathology testing and at assisting medical doctors in their treatment choices and/or at providing better monitoring of the evolution of their patients’ tumor.

Michäel Herman, Business Development Director of OncoDNA, said: “Malaysia was one of the few countries left without OncoDNA presence in Southeast Asia. It’s now settled with this new partnership. Genesis Genome is a young and ambitious company who will for sure bring OncoDEEP in oncologists’ daily practice to help many Malaysian patients. Their dynamism and great knowledge of the market have allowed them to the secure a minimum of sales for the first year, granting them with the exclusivity on the Malaysian market”

About OncoDNA SA
Based in Belgium, OncoDNA is an affiliated company of IPG (Institute of Pathology and Genetics) and is a leading company specialized in the personalized analysis of tumor DNA. OncoDNA currently has two services, OncoDEEP and OncoTRACE (for RUO), that lead the way in the field of cancer precision medicine as they combine targeted sequencing and molecular pathology analyses. These medical innovations assist medical doctors with treatment choice and/or provide better monitoring of tumor evolution in patients. For more information, please visit

About Genesis Genome
Genesis Genome is a company that provides molecular diagnostic testing that delivers the right treatments at the right time, to the right patient, every time.

For more information, contact:

Michäel Herman

Business Development Director
1 Rue Louis Breguet
6041 Gosselies, Belgium
Tel. +32 71 347899

Kelly Teo

Managing Director
Genesis Genome Sdn Bhd (1137905H)
Level 41 Vista Tower, The Intermark, 348 Jalan Tun Razak 50400 KL Malaysia
Tel. +603 2690 1393